Artificial intelligence is rapidly reshaping the surgical landscape, promising to enhance decision-making, improve patient outcomes, and optimize operational efficiency. With its recent $180 million Series C funding round, Caresyntax is at the forefront of this transformation, leveraging AI-driven insights to address inefficiencies and risks in the operating room.

During a panel at LSI Europe ’24, Henry Peck, CBO of LSI, sat down with Caresyntax CMIO Dr. Bruce Ramshaw and Cure Capital Advisors CEO David Cubbin to discuss the company’s journey, the impact of AI in surgery, and what this funding round means for the future of precision surgery.

The Problem: Surgery Remains Risky and Inefficient

Despite advances in medtech, surgery remains a high-risk, high-cost domain. “The spend in the operating room and in surgery is $1.7 trillion across the US and the EU annually, but there’s up to a 15% risk of complications,” noted Cubbin. “50% of liability insurance underwriting is related to surgery, and 60% of insurance spend occurs as a result of perioperative actions.”

Dr. Ramshaw echoed these concerns, emphasizing that fragmented data within healthcare systems prevents meaningful improvements in patient outcomes. “We have data that ends up in data jails in every little fragment of healthcare, and we need to free up that data and put it in context,” he said.

Caresyntax aims to solve these challenges by integrating AI into surgical workflows, creating a data-driven platform that improves efficiency, enhances decision-making, and reduces complications.

How AI in Surgery is Revolutionizing the OR

The power of AI lies in its ability to analyze massive amounts of surgical data, recognize patterns, and provide real-time insights that improve patient care. The Caresyntax platform collects and contextualizes intraoperative data to help surgeons and hospitals optimize decision-making.

Dr. Ramshaw highlighted the importance of this approach:

“Our vision is to have a data and analytics platform available for all of healthcare, anywhere in the world. If clinicians can access real-time, AI-driven insights, they can make better decisions for their patients and improve overall healthcare value.”

By leveraging AI, Caresyntax has already demonstrated significant improvements:

• 33% reduction in hospital length of stay
• 54% reduction in opioid usage
• 93% improvement in on-time case starts

These data-driven results illustrate how AI is not just a buzzword—it is actively shaping a more efficient and effective surgical ecosystem.

The Journey to $180M: A Strategic Investment in AI and Precision Surgery

Securing funding at this scale is no small feat, particularly in a medtech investment climate that has become more selective. The $180 million round includes an $80 million equity component and a $100 million debt facility structured to support both organic growth and strategic medtech M&A activity.

Cubbin, an early investor in Caresyntax, explained the funding approach:

“This is about scaling the business strategically. The $100 million debt component allows us to refinance existing debt, invest in growth, and selectively pursue M&A opportunities. Caresyntax has been incredibly strong in increasing its revenue per account—acquiring companies that align with our vision will only accelerate that success.”

Dr. Ramshaw emphasized that the funding would fuel Caresyntax’s ability to enhance AI-driven analytics and expand partnerships with hospitals, payors, and medtech companies.

“We want to bring all healthcare stakeholders into this ecosystem. AI in surgery should not just be about making operations more efficient—it should also drive systemic improvements in patient care and hospital sustainability.”

M&A Strategy: Scaling AI in Surgery Through Acquisitions

One of the most intriguing aspects of Caresyntax’s funding strategy is its focus on mergers and acquisitions. Rather than solely relying on organic growth, the company is looking to acquire complementary technologies and customer bases to expand its AI-driven platform.

“We’re always evaluating whether to build, borrow, or buy,” said Cubbin. “Strategic acquisitions will allow us to accelerate adoption, expand our data insights, and strengthen our position as the leading AI-powered surgical intelligence platform.”

This strategy underscores the increasing importance of consolidation in the AI-driven healthcare space. Companies that can integrate diverse datasets and scale AI solutions efficiently will have a distinct competitive advantage.

What’s Next for Caresyntax?

As Caresyntax looks to the future, the company remains committed to its mission of using AI to improve surgical outcomes, reduce inefficiencies, and drive value across healthcare systems.

“The future of AI in surgery is about transforming the way healthcare operates,” said Dr. Ramshaw. “Right now, we still treat surgery as a one-size-fits-all model. AI allows us to personalize patient care, optimize workflows, and, ultimately, make surgery safer and more effective.”

With its latest funding round, Caresyntax is well-positioned to lead this transformation. The company’s vendor-agnostic, data-driven approach ensures that hospitals, medtech companies, and payors alike can benefit from its AI-powered insights.

As AI continues to redefine surgical precision, companies like Caresyntax are proving that data-driven healthcare solutions are not just the future—they’re happening now.

Final Thoughts

Caresyntax’s $180 million Series C funding round signals a pivotal moment for AI in surgery. The combination of real-time data analytics, machine learning, and AI-driven surgical intelligence is setting a new standard for operating rooms worldwide.

As Cubbin summarized:

“If anyone can achieve what they’re setting out to achieve, it’s the team at Caresyntax. They are not just building an AI-powered platform—they’re redefining what surgical excellence looks like.”

With AI at the helm, the future of surgery is smarter, safer, and more efficient than ever before.

Want to hear more insights like this? Join us for our upcoming medical technology conference from March 17th to 21st in Dana Point, CA.